Enanta Pharmaceuticals Inc., of Watertown, Mass., said Novartis AG, of Basel, Switzerland, has advanced EDP-239, Enanta's NS5A inhibitor for hepatitis C virus, into drug combination studies with alisporivir (DEB025), a cyclophilin inhibitor being developed by Novartis. These combination studies are part of Enanta's existing collaboration with Novartis for the development of new combination therapies.